Lung Cancer

Official Title: Testing The Addition Of A Type Of Drug Called Immunotherapy To The Usual Chemotherapy Treatment For Non-Small Cell Lung Cancer

Study Purpose: To compare the usual treatment alone to using pembrolizumab plus the usual treatment.  The addition of pembrolizumab to the usual treatment could prevent it from returning.

Status: Recruiting

Official Title: PHASE 2 RANDOMIZED TRIAL OF NEOADJUVANT OR PALLIATIVE CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY FOR PERITONEAL MESOTHELIOMA

Study Purpose: To determine whether frontline treatment with carboplatin, pemetrexed, bevacizumab and atezolizumab results in a superior best response rate than carboplatin, pemetrexed and bevacizumab in patients with peritoneal mesothelioma

Status: Available

Official Title: Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Study Purpose: To study the genes of tumor cells to determine if these results will help physicians select the best treatment options for patients with genetic changes. 

Status: Recruiting

Official Title: Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR

Study Purpose: To evaluate the best objective response rate of AZD9291 (osimertinib) among patients with EGFR exon 20 insertions.

Status: Recruiting

Official Title: A Phase III Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib versus Sotorasib or Divarasib in patients with previously treated KRAS G12C-positive Advanced or Metastatic NSCLC.

Study Purpose: To evaluate the effectiveness of divarasib compared to currently approved Sotorasib or Adagrasib.

Status: Recruiting

Official Title: A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD-L1-high NSCLC 

Study Purpose: This study will test new combination of experimental drugs, dostarlimab + belrestotug, which have not yet been approved by the FDA.  The study will also evaluate the activity of pembrolizumab given in combination with placebo in lung cancer. Pembrolizumab has been approved by the FDA to treat the type of lung cancer you have been diagnosed with.

Status: Pending

Official Title: Testing The Addition Of Radiation Therapy To The Usual Immune Therapy Treatment (Atezolizumab) For Patients With Extensive Stage Small Cell Lung Cancer

Study Purpose: To determine if can we extend the time without your extensive small cell lung cancer growing or spreading by adding radiation therapy to the usual treatment for this type of cancer.

Status: Recruiting

Official Title: Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed By Concurrent Mediastinal Chemoradiation For Locally Advanced Non-Small Cell Lung Cancer 

Study Purpose: To compare overall survival in patients with Stage II-IIIC inoperable Non-small cell lung cancer comparing conventional radiation with chemotherapy  to stereotactic body radiation and conventional  radiation along with chemotherapy

Status: Recruiting

Official Title: Targeted Treatment for Advanced Non-small Cell Lung Cancer

Study Purpose: To find out if a targeted or immunotherapy treatment will have an effect on specific genes and proteins in the tumor.

Status: Recruiting

Official Title: Testing Whether the Of Brain Scans Alone Instead Of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients with Small Cell Lung Cancer

Study Purpose: To see if the use of brain scans alone instead of brain scans plus preventive brain radiation affect the lifespan of patients with small cell lung cancer.

Status: Recruiting